US House appropriators propose increasing the Food and Drug Administration’s funding for developing a regulatory pathway for lawful use of hemp-derived cannabidiols in non-drug products but also expect an uptick in the agency’s enforcement in the current marketplace.
Appropriation Committee members included that suggestion in their report accompanying legislation proposing the agency’s fiscal 2021 budget
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?